COLL
Collegium Pharmaceutical, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$23.53
−0.72%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 808.2M | 780.6M | 631.4M | 566.8M | 463.9M |
| Cost of Revenue | 323.1M | 317.3M | 254.1M | 240.6M | 254.4M |
| Gross Profit | 485.1M | 463.3M | 377.3M | 326.2M | 209.5M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | 4.0M |
| SG&A Expense | 239.8M | 276.2M | 183.0M | 159.2M | 172.2M |
| General & Admin Expense | 106.6M | — | 172.3M | — | — |
| Selling & Marketing Expense | — | — | 10.7M | — | — |
| Other Expenses | 86.8M | — | 24.5M | — | — |
| Total Operating Expenses | 326.6M | 276.2M | 207.4M | 159.2M | 176.2M |
| Cost and Expenses | 649.7M | 593.5M | 461.6M | 399.8M | 430.6M |
| Operating Income (EBIT) | 158.5M | 187.1M | 169.9M | 167.0M | 33.3M |
| Non-Operating | |||||
| Interest Income | 12.7M | 11.3M | 14.0M | 15.6M | 1.0M |
| Interest Expense | 161.9M | 82.3M | 74.0M | 83.3M | 63.2M |
| Net Interest Income | (149.3M) | (71.0M) | (60.0M) | (67.7M) | (62.2M) |
| Other Non-Op Income/Expense | (80.8M) | (94.5M) | (71.3M) | (91.2M) | (62.2M) |
| Non-Operating Income (excl Interest) | (81.1M) | 12.2M | (2.6M) | 7.9M | (1.0M) |
| EBT (Pre-Tax Income) | 77.7M | 92.6M | 98.6M | 75.7M | (28.8M) |
| Income Tax Expense | 29.8M | 29.7M | 29.4M | 27.6M | (3.8M) |
| Bottom Line | |||||
| Net Income | 47.9M | 62.9M | 69.2M | 48.2M | (25.0M) |
| Earnings from Cont. Ops | 47.9M | 62.9M | 69.2M | 48.2M | (25.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 51.0M | 68.9M | 75.1M | 54.0M | (25.0M) |
| Per Share | |||||
| Basic EPS | $1.53 | $1.98 | $2.14 | $1.60 | ($0.74) |
| Diluted EPS | $1.24 | $1.73 | $1.86 | $1.29 | ($0.74) |
| Revenue Per Share | $24.90 | $24.62 | $19.57 | $16.80 | $13.71 |
| Shares | |||||
| Basic Shares Outstanding | 32.5M | 31.7M | 32.3M | 33.7M | 33.8M |
| Diluted Shares Outstanding | 32.5M | 39.7M | 40.4M | 41.8M | 33.8M |
| Profitability Metrics | |||||
| EBITDA | 586.6M | 401.0M | 341.7M | 308.3M | 173.3M |
| D&A | 346.9M | 226.1M | 169.2M | 149.3M | 138.9M |
| EBIT | 239.6M | 174.9M | 172.5M | 159.1M | 34.4M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026